UPC_APP_13067/2025

The Munich Local Division rejected Ascendis Pharma's preliminary objection to jurisdiction in the infringement action brought by BioMarin Pharmaceutical concerning EP 3 175 863 (C-Type Natriuretic Peptide variants for achondroplasia treatment). The court found that the opt-out withdrawal was effective and that sufficient acts of infringement were alleged in Germany.